18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy
Epilepsy is a neurological disorder characterized by epileptic seizures as a result of excessive neuronal activity in the brain. Approximately 65 million people worldwide suffer from epilepsy; 20–40% of them are refractory to medication therapy. Early detection of disease is crucial in the managemen...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2016-09-01
|
| Series: | Radiology and Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/raon-2016-0032 |
| _version_ | 1818669005355876352 |
|---|---|
| author | Hodolic Marina Topakian Raffi Pichler Robert |
| author_facet | Hodolic Marina Topakian Raffi Pichler Robert |
| author_sort | Hodolic Marina |
| collection | DOAJ |
| description | Epilepsy is a neurological disorder characterized by epileptic seizures as a result of excessive neuronal activity in the brain. Approximately 65 million people worldwide suffer from epilepsy; 20–40% of them are refractory to medication therapy. Early detection of disease is crucial in the management of patients with epilepsy. Correct localization of the ictal onset zone is associated with a better surgical outcome. The modern non-invasive techniques used for structural-functional localization of the seizure focus includes electroencephalography (EEG) monitoring, magnetic resonance imaging (MRI), single photon emission tomography/computed tomography (SPECT/CT) and positron emission tomography/computed tomography (PET/CT). PET/CT can predict surgical outcome in patients with refractory epilepsy. The aim of the article is to review the current role of routinely used tracer 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) as well as non routinely used 18F-Flumazenil (18F-FMZ) tracers PET/CT in patients with refractory epilepsy. |
| first_indexed | 2024-12-17T06:45:20Z |
| format | Article |
| id | doaj.art-f1a8a91ef5274ba3a52b9bb8244c7e07 |
| institution | Directory Open Access Journal |
| issn | 1581-3207 |
| language | English |
| last_indexed | 2024-12-17T06:45:20Z |
| publishDate | 2016-09-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Radiology and Oncology |
| spelling | doaj.art-f1a8a91ef5274ba3a52b9bb8244c7e072022-12-21T21:59:46ZengSciendoRadiology and Oncology1581-32072016-09-0150324725310.1515/raon-2016-0032raon-2016-003218F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsyHodolic MarinaTopakian Raffi0Pichler Robert1 Department of Neurology, Klinikum Wels-Grieskirchen, Wels, Austria Institute of Nuclear Medicine, Kepler Universitätsklinikum, Neuromed Campus, Linz, AustriaEpilepsy is a neurological disorder characterized by epileptic seizures as a result of excessive neuronal activity in the brain. Approximately 65 million people worldwide suffer from epilepsy; 20–40% of them are refractory to medication therapy. Early detection of disease is crucial in the management of patients with epilepsy. Correct localization of the ictal onset zone is associated with a better surgical outcome. The modern non-invasive techniques used for structural-functional localization of the seizure focus includes electroencephalography (EEG) monitoring, magnetic resonance imaging (MRI), single photon emission tomography/computed tomography (SPECT/CT) and positron emission tomography/computed tomography (PET/CT). PET/CT can predict surgical outcome in patients with refractory epilepsy. The aim of the article is to review the current role of routinely used tracer 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) as well as non routinely used 18F-Flumazenil (18F-FMZ) tracers PET/CT in patients with refractory epilepsy.https://doi.org/10.1515/raon-2016-0032epilepsynuclear medicinepet/ct18f-fdg18f-flumazenil |
| spellingShingle | Hodolic Marina Topakian Raffi Pichler Robert 18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy Radiology and Oncology epilepsy nuclear medicine pet/ct 18f-fdg 18f-flumazenil |
| title | 18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy |
| title_full | 18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy |
| title_fullStr | 18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy |
| title_full_unstemmed | 18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy |
| title_short | 18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy |
| title_sort | 18f fluorodeoxyglucose and 18f flumazenil positron emission tomography in patients with refractory epilepsy |
| topic | epilepsy nuclear medicine pet/ct 18f-fdg 18f-flumazenil |
| url | https://doi.org/10.1515/raon-2016-0032 |
| work_keys_str_mv | AT hodolicmarina 18ffluorodeoxyglucoseand18fflumazenilpositronemissiontomographyinpatientswithrefractoryepilepsy AT topakianraffi 18ffluorodeoxyglucoseand18fflumazenilpositronemissiontomographyinpatientswithrefractoryepilepsy AT pichlerrobert 18ffluorodeoxyglucoseand18fflumazenilpositronemissiontomographyinpatientswithrefractoryepilepsy |